Predicting severe blood cell drops in nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at how likely it is for people with nasopharyngeal carcinoma to experience a severe drop in blood cell counts (myelosuppression) during treatment. By tracking risk, doctors may be better able to prevent or manage this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose and throat).
- Your doctor must plan to give you treatment that works throughout the body (like chemotherapy).
- You cannot have other serious health problems that are not well controlled, like unstable heart disease, poorly managed diabetes, or severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy drugs for people with nasopharyngeal cancer that has spread or come back. The goal is to see if it can help control the cancer and improve survival.
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This study looks at tissue and blood samples from people already treated for nasopharyngeal carcinoma to find markers that predict how well treatment works and to identify new ways to treat the cancer. It may help doctors personalise care in the future.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.